Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ
Lancet. 2013 381 (9865): 468-75

PMID: 23234725 · DOI:10.1016/S0140-6736(12)61425-1

MeSH Terms (21)

Adenine Adult Biopsy, Needle Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hepatitis B, Chronic Hepatitis B virus Humans Immunohistochemistry Male Middle Aged Organophosphonates Reverse Transcriptase Inhibitors Safety Management Severity of Illness Index Tenofovir Time Factors Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: